Biotech Bay
Filter News
Found 84,924 articles
-
Cytovale's Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
3/19/2024
Cytovale® announced new data that demonstrates how its IntelliSep® test reduced cost of care and improved efficiency of sepsis care for a large U.S. academic center.
-
SPEVIGO® approved for expanded indications in China and the US
3/19/2024
Boehringer Ingelheim announced that the US FDA has approved SPEVIGO® injection for the treatment of generalized pustular psoriasis in adults and pediatric patients aged 12 and above weighing ≥40 kg.5 This approval follows the Chinese National Medical Products Administration’s recent approval of SPEVIGO® for the reduction of occurrence of generalized pustular psoriasis in adolescents from 12 years of age with a body weight ≥40 kg and adults.
-
Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
3/19/2024
Innovent Biologics, Inc. announced that the primary endpoint has been met in the second Phase 2 clinical study of efdamrofusp alfa high-dose, a recombinant human VEGFR-Fc-Human CR1 fusion protein injection, in Chinese subjects with neovascular age-related macular degeneration.
-
YourChoice Therapeutics Scientific Advisory Board member updates phase 1a study for male birth control candidate at ACS Spring 24
3/19/2024
YourChoice Therapeutics, a San Francisco biotech startup developing the first hormone-free male birth control pill, announced today that Gunda Georg, YCT-529’s co-inventor, provided an update on its phase 1a clinical study for the first hormone-free male birth control pill, YCT-529, at the American Chemical Society (ACS) 2024 Spring Meeting.
-
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
3/18/2024
Aligos Therapeutics, Inc. today announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH). Screening of subjects has begun at clinical study sites across the U.S.
-
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - March 18, 2024
3/18/2024
CytomX Therapeutics, Inc. today announced that the first clinical candidate in its TCB agreement with Astellas has entered into GLP toxicology studies which triggers a $5 million payment to CytomX.
-
ConKay Medical Systems Raises $1.8M in Oversubscribed Seed Funding Round
3/18/2024
ConKay Medical Systems, a medtech start-up company developing a unique device for treating patients suffering from valvular regurgitation, has closed an oversubscribed $1.8M seed round.
-
Aquedeon Medical Announces First Patient Enrolled in the IDE Study of Duett(TM) Vascular Graft System
3/18/2024
Aquedeon Medical, Inc. is pleased to announce a significant milestone with initiation of its investigational device exemption (IDE) clinical trial to study for the Duett(TM) Vascular Graft System.
-
Maplight Therapeutics Expands Executive Leadership Team With Appointment of Vishwas Setia as Chief Financial Officer
3/18/2024
MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of patients suffering from debilitating CNS disorders, announced the appointment of Vishwas Setia as Chief Financial Officer.
-
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - March 18, 2024
3/18/2024
Annexon, Inc. announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.
-
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
3/18/2024
Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B Convertible Preferred Stock (the “Series B Preferred”) for shares of common stock pursuant to an agreement with stockholders affiliated with Viking Global Investors (“Viking”) and Casdin Capital (“Casdin").
-
Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Treatment of Liver Cancer Using GPC3-Targeting ARTEMIS® T-cell Therapy
3/18/2024
Eureka Therapeutics, Inc. today announced the advancement of its ARYA-3 clinical trial to Phase II ( NCT04864054 ).
-
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
3/18/2024
Protagonist Therapeutics, Inc. announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January 31, 2024.
-
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
3/18/2024
Tenaya Therapeutics today announced the publication of its preclinical research related to its gene therapy candidate, TN-401, in the current issue of Nature Communications Medicine.
-
The American Cancer Society and Color Health Announce Expansion of a Comprehensive Cancer Care Solution
3/18/2024
The American Cancer Society and Color Health announced an expansion of their program to form a comprehensive cancer solution for employers and labor unions to support their employee and member populations across all stages of the cancer journey.
-
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB®
3/18/2024
Scilex Holding Company today announced that it has responded to questions on the product composition in the ELYXYB patent from Health Canada’s Office of Patented Medicines and Liaison (OPML) during review of a New Drug Submission (“NDS”) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB® for acute treatment of migraine with or without aura in Canada.
-
QT Imaging Holdings names Dr. Raluca Dinu as Acting Chief Executive Officer and Anastas Budagov as Chief Financial Officer
3/18/2024
QT Imaging Holdings, Inc. a medical device company engaged in research, development, and commercialization of innovative body imaging systems, announced that the Board of Directors has appointed former GigCapital5, Inc. CEO Dr. Raluca Dinu as Active Chief Executive Officer and member of the Board of Directors, effective March 12, 2024.
-
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
3/18/2024
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, announced today that participants from Japan, via a collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN), will have their samples tested using GRAIL’s novel risk classification test on its Methylation Platform.
-
Nodexus Names William Rhodes Executive Chairman of the Board
3/18/2024
Nodexus Inc. today announced that William (Bill) Rhodes has been named Executive Chairman of the company’s Board of Directors.
-
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
3/18/2024
Mainz Biomed N.V. will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.